Safety of subcutaneous octreotide in patients with sulfonylurea-induced hypoglycemia and congestive heart failure

Annals of Pharmacotherapy

Volumn 44, Issue 2, 2010, Pages 387-390

  Vallurupalli, Srikanth ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heart failure; Hypoglycemia; Octreotide; Safety; Sulfonylurea

Indexed keywords

ACETYLSALICYLIC ACID; CARBOHYDRATE; CARVEDILOL; CITALOPRAM; DIURETIC AGENT; EZETIMIBE; FERROUS SULFATE; FUROSEMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; HYDRALAZINE; OCTREOTIDE; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAM; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; LUNG CONGESTION; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYSTOLIC DYSFUNCTION; THORAX RADIOGRAPHY; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; GASTROINTESTINAL AGENTS; HEART FAILURE; HUMANS; HYPOGLYCEMIA; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; OCTREOTIDE; SEVERITY OF ILLNESS INDEX; SULFONYLUREA COMPOUNDS;

EID: 76149143985     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M433     Document Type: Article

References (18)

1. Lheureux PE, Zahir S, Penaloza A, Gris M. Bench-to-bedside review: antidotal treatment of sulfonylurea-induced hypoglycaemia with octreotide. Crit Care 2005;9:543-9.
2. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997;157:1681-6.
3. Vallurupalli S, Huesmann G, Gregory J, Jakoby MG. Levofloxacin-associated hypoglycaemia complicated by pontine myelinolysis and quadriplegia. Diabet Med 2008;25:856-9.
4. Package insert. Sandostatin immediate release (octreotide acetate). Novartis. http://www.pharma.us.novartis.com/product/pi/pdf/sandostatin-inj.pdf (accessed 2009 July 9).
5. Harrigan RA, Nathan MS, Beattie P. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity and treatment. Ann Emerg Med 2001;38:68-78.
6. Boyle PJ. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab 1993;76:752-6.
7. Fasano CJ, O'Malley G, Dominici P, Aguilera E, Latta DR. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Ann Emerg Med 2008;51:400-6.
8. Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN. Drug-induced disorders of glucose tolerance. Ann Intern Med 1993;118:529-39.
9. Crawford BAL, Perera C. Octreotide treatment for sulfonylurea-induced hypoglycaemia. Med J Aust 2004;180:540-1.
10. Fleseriu M, Skugor M, Chinnappa P, et al. Successful treatment of sulfonylurea-induced prolonged hypoglycemia with use of octreotide. Endocr Pract 2006;12:635- 40.
11. Fatti LM, Scacchi M, Lavezzi E, et al. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin Endocrinol 2006;65:626-30.
12. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2007;92:1743-7.
13. Day SM, Gu J, Polak JM, Bloom SR. Somatostatin in the human heart and comparison with guinea pig and rat heart. Br Heart J 1985;53:153-7.
14. Dilger JA, Rho EH, Que FG, et al. Octreotide-induced bradycardia and heart block during surgical resection of a carcinoid tumor. Anesth Analg 2004;98:318-20.
15. Leclercq F, Fille A, Albat B, Bringer J, Grolleau R, Jaffiol C. Congestive heart failure worsening with octreotide in acromegalic patients. Lancet 1991;338:1272-3.
16. Albat B, Leclercq F, Serre I, et al. Heart transplantation for terminal congestive heart failure in an acromegalic patient. Eur Heart J 1993;14: 1572-5.
17. Chanson P, Timsit J, Harris AG. Heart failure and octreotide in acromegaly. Lancet 1992;339:242-3.
18. Eryol NK, Güven M, Topsakal R, et al. The effects of octreotide in dilated cardiomyopathy: an open-label trial in 12 patients. Jpn Heart J 2004; 45:613-21.